SubHero Banner
Text

Copiktra (duvelisib) – New orphan drug approval

September 24, 2018 - Verastem Oncology announced the FDA approval of Copiktra (duvelisib), for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies and for relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.

Download PDF